BACKGROUND: Fetuin-A is a serum protein that inhibits ectopic vascular calcification and is present in lower concentrations in end-stage renal disease than in healthy controls. Whether fetuin-A concentrations are also lower in the setting of mild-to-moderate chronic kidney disease (CKD) is unknown. METHODS: We evaluated the associations of several parameters of kidney function including measured 24 h urinary creatinine clearance (CrCl), estimated glomerular filtration rate (GFR) by the Mayo Clinic quadratic GFR equation (qGFR), serum cystatin-C concentrations, and urinary albumin-to-creatinine ratio with serum fetuin-A concentrations in 970 outpatients with coronary artery disease. We used general linear models to determine the adjusted mean fetuin-A concentrations within each kidney function category. RESULTS: The mean age of the study sample was 67 years, 82% were male, 71% had hypertension and 26% had diabetes mellitus. In adjusted analysis, we observed no significant differences in mean fetuin-A concentrations across groups defined by CrCl, qGFR, or albumin-to-creatinine ratio groups. For example, adjusted mean fetuin-A concentrations were 0.66 g/l in participants with CrCl > 90, 60-90 and 45-60 ml/min/1.73 m(2), and 0.65 g/l in participants with CrCl < 45 ml/min/1.73 m(2). Higher serum cystatin-C (indicating worse kidney function) was associated with higher adjusted mean serum fetuin-A concentrations (lowest quartile 0.62 g/l, highest quartile 0.68 g/l; P for trend <0.001). CONCLUSIONS: Among ambulatory patients with coronary artery disease, there is no evidence that mild-to-moderate CKD is associated with lower concentrations of serum fetuin-A compared with persons with normal renal function. The mechanisms explaining the association between CKD and vascular calcification remain elusive.
BACKGROUND:Fetuin-A is a serum protein that inhibits ectopic vascular calcification and is present in lower concentrations in end-stage renal disease than in healthy controls. Whether fetuin-A concentrations are also lower in the setting of mild-to-moderate chronic kidney disease (CKD) is unknown. METHODS: We evaluated the associations of several parameters of kidney function including measured 24 h urinary creatinine clearance (CrCl), estimated glomerular filtration rate (GFR) by the Mayo Clinic quadratic GFR equation (qGFR), serum cystatin-C concentrations, and urinary albumin-to-creatinine ratio with serum fetuin-A concentrations in 970 outpatients with coronary artery disease. We used general linear models to determine the adjusted mean fetuin-A concentrations within each kidney function category. RESULTS: The mean age of the study sample was 67 years, 82% were male, 71% had hypertension and 26% had diabetes mellitus. In adjusted analysis, we observed no significant differences in mean fetuin-A concentrations across groups defined by CrCl, qGFR, or albumin-to-creatinine ratio groups. For example, adjusted mean fetuin-A concentrations were 0.66 g/l in participants with CrCl > 90, 60-90 and 45-60 ml/min/1.73 m(2), and 0.65 g/l in participants with CrCl < 45 ml/min/1.73 m(2). Higher serum cystatin-C (indicating worse kidney function) was associated with higher adjusted mean serum fetuin-A concentrations (lowest quartile 0.62 g/l, highest quartile 0.68 g/l; P for trend <0.001). CONCLUSIONS: Among ambulatory patients with coronary artery disease, there is no evidence that mild-to-moderate CKD is associated with lower concentrations of serum fetuin-A compared with persons with normal renal function. The mechanisms explaining the association between CKD and vascular calcification remain elusive.
Authors: Geoffrey A Block; David M Spiegel; James Ehrlich; Ravindra Mehta; Jill Lindbergh; Albert Dreisbach; Paolo Raggi Journal: Kidney Int Date: 2005-10 Impact factor: 10.612
Authors: Rajnish Mehrotra; Ralf Westenfeld; Peter Christenson; Matthew Budoff; Eli Ipp; Junichiro Takasu; Ajay Gupta; Keith Norris; Markus Ketteler; Sharon Adler Journal: Kidney Int Date: 2005-03 Impact factor: 10.612
Authors: Markus Ketteler; Philipp Bongartz; Ralf Westenfeld; Joachim Ernst Wildberger; Andreas Horst Mahnken; Roland Böhm; Thomas Metzger; Christoph Wanner; Willi Jahnen-Dechent; Jürgen Floege Journal: Lancet Date: 2003-03-08 Impact factor: 79.321
Authors: Glenn M Chertow; Paolo Raggi; Scott Chasan-Taber; Juergen Bommer; Herwig Holzer; Steven K Burke Journal: Nephrol Dial Transplant Date: 2004-04-21 Impact factor: 5.992
Authors: Sarah A Aroner; Kenneth J Mukamal; David E St-Jules; Matthew J Budoff; Ronit Katz; Michael H Criqui; Matthew A Allison; Ian H de Boer; David S Siscovick; Joachim H Ix; Majken K Jensen Journal: Am J Epidemiol Date: 2016-11-17 Impact factor: 4.897
Authors: Joachim H Ix; Michel Chonchol; Gail A Laughlin; Michael G Shlipak; Mary A Whooley Journal: Am J Kidney Dis Date: 2011-08-19 Impact factor: 8.860
Authors: Gail A Laughlin; Kevin M Cummins; Christina L Wassel; Lori B Daniels; Joachim H Ix Journal: J Am Coll Cardiol Date: 2012-05-08 Impact factor: 24.094
Authors: Joachim H Ix; Glenn M Chertow; Michael G Shlipak; Vincent M Brandenburg; Markus Ketteler; Mary A Whooley Journal: Circulation Date: 2007-05-07 Impact factor: 29.690
Authors: Joachim H Ix; Christina L Wassel; Alka M Kanaya; Eric Vittinghoff; Karen C Johnson; Annemarie Koster; Jane A Cauley; Tamara B Harris; Steven R Cummings; Michael G Shlipak Journal: JAMA Date: 2008-07-09 Impact factor: 56.272
Authors: Joachim H Ix; Christina L Wassel; Douglas C Bauer; Damon Toroian; Frances A Tylavsky; Jane A Cauley; Tamara B Harris; Paul A Price; Steven R Cummings; Michael G Shlipak Journal: J Bone Miner Res Date: 2009-03 Impact factor: 6.741